Skip to content
2000
image of Computational Exploration of Flavonoids as HCV NS3/4A Protease Inhibitors: Advancing Antiviral Therapies to Mitigate Liver Cancer Risk

Abstract

Introduction

Hepatitis C virus (HCV) remains a major global health challenge, driving chronic hepatitis C (CHC) progression to severe liver diseases, including hepatocellular carcinoma (HCC). Direct-acting antivirals (DAAs) have transformed HCV treatment by achieving high sustained virological response (SVR) rates. However, limitations such as resistance, reinfection, and restricted accessibility emphasize the urgent need for novel therapeutic approaches. Among HCV therapeutic targets, the NS3/4A protease is critical for viral replication and immune evasion, positioning it as a prime focus for innovative drug discovery.

Methods

A comprehensive computational approach was adopted to evaluate flavonoids, natural compounds with known antiviral and anticancer properties, as potential inhibitors of the HCV NS3/4A protease. A curated flavonoid library was subjected to virtual screening using molecular docking techniques. Top-ranked flavonoids were further assessed based on binding affinity, dissociation constants, and key protein-ligand interactions. Pharmacokinetic profiling, molecular dynamics simulations, MM/PBSA energy calculations, and principal component analysis were performed to validate the most promising candidate.

Results

The top ten scoring flavonoids demonstrated strong binding affinities and stable interactions with key catalytic residues of the NS3/4A protease. CID 100943380 emerged as the most promising candidate, exhibiting favorable pharmacokinetic properties and sustained stability throughout molecular dynamics simulations. MM/PBSA and PCA analyses further confirmed its robust binding and conformational stability.

Discussion

The findings highlight flavonoids as promising inhibitors of NS3/4A protease, supporting their potential for further antiviral development.

Conclusion

This investigation identifies 10 flavonoids with high potential as NS3/4A protease inhibitors, providing a basis for future biological validation and safer drug development.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128386884250904063752
2025-10-07
2026-02-26

  • From This Site

    /content/journals/cpd/10.2174/0113816128386884250904063752
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ahmed K. Jha S. Oncoviruses: How do they hijack their host and current treatment regimes. Biochim. Biophys. Acta Rev. Cancer 2023 1878 5 188960 10.1016/j.bbcan.2023.188960 37507056
    [Google Scholar]
  2. Chang Y Moore PS Weiss RA Human oncogenic viruses: Nature and discovery. Philos Trans R Soc Lond B Biol Sci 1732 372 1732 20160264 10.1098/rstb.2016.0264
    [Google Scholar]
  3. Akram N. Imran M. Noreen M. Oncogenic role of tumor viruses in humans. Viral Immunol. 2017 30 1 20 27 10.1089/vim.2016.0109 27830995
    [Google Scholar]
  4. Bandiera S. Billie Bian C. Hoshida Y. Baumert T.F. Zeisel M.B. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr. Opin. Virol. 2016 20 99 105 10.1016/j.coviro.2016.09.010 27741441
    [Google Scholar]
  5. Siegel R.L. Giaquinto A.N. Jemal A. Cancer statistics, 2024. CA Cancer J. Clin. 2024 74 1 12 49 10.3322/caac.21820 38230766
    [Google Scholar]
  6. Nawaz A. Manzoor A. Ahmed S. Therapeutic approaches for chronic hepatitis C: A concise review. Front. Pharmacol. 2024 14 1334160 10.3389/fphar.2023.1334160 38283838
    [Google Scholar]
  7. Tempera I. Lieberman P.M. Oncogenic viruses as entropic drivers of cancer evolution. Front Virol 2021 1 753366 10.3389/fviro.2021.753366 35141704
    [Google Scholar]
  8. Maticic M. Pirnat Z. Leicht A. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct. J. 2020 17 1 89 10.1186/s12954‑020‑00439‑3 33213481
    [Google Scholar]
  9. Chatel-Chaix L. Baril M. Lamarre D. Hepatitis C virus NS3/4A protease inhibitors: a light at the end of the tunnel. Viruses 2010 2 8 1752 1765 10.3390/v2081752 21994705
    [Google Scholar]
  10. Stanciu C. Muzica C.M. Girleanu I. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin. Pharmacother. 2021 22 13 1729 1741 10.1080/14656566.2021.1921737 33896315
    [Google Scholar]
  11. Scheel T.K.H. Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 2013 19 7 837 849 10.1038/nm.3248 23836234
    [Google Scholar]
  12. Vescovo T. Refolo G. Vitagliano G. Fimia G.M. Piacentini M. Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma. Clin. Microbiol. Infect. 2016 22 10 853 861 10.1016/j.cmi.2016.07.019 27476823
    [Google Scholar]
  13. Su F. Ioannou G.N. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. Curr. Hepatol. Rep. 2018 17 4 377 384 10.1007/s11901‑018‑0424‑8 30923667
    [Google Scholar]
  14. Atanasov A.G. Zotchev S.B. Dirsch V.M. Natural products in drug discovery: advances and opportunities. Nat. Rev. Drug Discov. 2021 20 3 200 216 10.1038/s41573‑020‑00114‑z 33510482
    [Google Scholar]
  15. Abou Baker D.H. An ethnopharmacological review on the therapeutical properties of flavonoids and their mechanisms of actions: A comprehensive review based on up to date knowledge. Toxicol. Rep. 2022 9 445 469 10.1016/j.toxrep.2022.03.011 35340621
    [Google Scholar]
  16. AlZahrani W.M. AlGhamdi S.A. Zughaibi T.A. Rehan M. Exploring the natural compounds in flavonoids for their potential inhibition of cancer therapeutic target MEK1 using computational methods. Pharmaceuticals (Basel) 2022 15 2 195 10.3390/ph15020195 35215307
    [Google Scholar]
  17. AlZahrani W.M. AlGhamdi S.A. Sohrab S.S. Rehan M. Investigating a library of flavonoids as potential inhibitors of a cancer therapeutic target MEK2 using in silico methods. Int. J. Mol. Sci. 2023 24 5 4446 10.3390/ijms24054446 36901876
    [Google Scholar]
  18. Suhail M. AlZahrani W.M. Shakil S. Analysis of some flavonoids for inhibitory mechanism against cancer target phosphatidylinositol 3-kinase (PI3K) using computational tool. Front. Pharmacol. 2023 14 1236173 10.3389/fphar.2023.1236173 37900167
    [Google Scholar]
  19. Rehan M. Mahmoud M.M. Tabrez S. Hassan H.M.A. Ashraf G.M. Exploring flavonoids for potential inhibitors of a cancer signaling protein PI3K kinase using computational methods. Anticancer Res. 2020 40 8 4547 4556 10.21873/anticanres.14460 32727785
    [Google Scholar]
  20. Rehan M. Ahmed F. Khan M.I. Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase. Front. Pharmacol. 2024 14 1231671 10.3389/fphar.2023.1231671 38273823
    [Google Scholar]
  21. Jamal M.S. Parveen S. Beg M.A. Anticancer compound plumbagin and its molecular targets: A structural insight into the inhibitory mechanisms using computational approaches. PLoS One 2014 9 2 e87309 10.1371/journal.pone.0087309 24586269
    [Google Scholar]
  22. Bachmetov L. Gal-Tanamy M. Shapira A. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J. Viral Hepat. 2012 19 2 e81 e88 10.1111/j.1365‑2893.2011.01507.x 22239530
    [Google Scholar]
  23. Shimizu J.F. Lima C.S. Pereira C.M. Flavonoids from Pterogyne nitens inhibit hepatitis C virus entry. Sci. Rep. 2017 7 1 16127 10.1038/s41598‑017‑16336‑y 29170411
    [Google Scholar]
  24. Shibata C. Ohno M. Otsuka M. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology 2014 462-463 42 48 10.1016/j.virol.2014.05.024 25092460
    [Google Scholar]
  25. Goldwasser J. Cohen P.Y. Lin W. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J. Hepatol. 2011 55 5 963 971 10.1016/j.jhep.2011.02.011 21354229
    [Google Scholar]
  26. Liao Y. Lv F. Quan T. Wang C. Li J. Flavonoids in natural products for the therapy of liver diseases: progress and future opportunities. Front. Pharmacol. 2024 15 1485065 10.3389/fphar.2024.1485065 39512816
    [Google Scholar]
  27. Ninfali P. Antonelli A. Magnani M. Scarpa E.S. Antiviral properties of flavonoids and delivery strategies. Nutrients 2020 12 9 2534 10.3390/nu12092534 32825564
    [Google Scholar]
  28. Pinzi L. Rastelli G. Molecular docking: Shifting paradigms in drug discovery. Int. J. Mol. Sci. 2019 20 18 4331 10.3390/ijms20184331 31487867
    [Google Scholar]
  29. Mohd Rehan . A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches. J. Mol. Graph. Model. 2015 62 226 234 10.1016/j.jmgm.2015.10.005 26500112
    [Google Scholar]
  30. Rehan M. An anti-cancer drug candidate OSI-027 and its analog as inhibitors of mTOR: Computational insights into the inhibitory mechanisms. J. Cell. Biochem. 2017 118 12 4558 4567 10.1002/jcb.26117 28475291
    [Google Scholar]
  31. Rehan M. Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches. PLoS One 2019 14 6 e0219180 10.1371/journal.pone.0219180 31247018
    [Google Scholar]
  32. Rehan M. Beg M.A. Parveen S. Damanhouri G.A. Zaher G.F. Computational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206. PLoS One 2014 9 10 e109705 10.1371/journal.pone.0109705 25329478
    [Google Scholar]
  33. Rehan M. Bajouh O.S. Virtual screening of naphthoquinone analogs for potent inhibitors against the cancer& 8208;signaling PI3K/AKT/mTOR pathway. J. Cell. Biochem. 2019 120 2 1328 1339 10.1002/jcb.27100 30298630
    [Google Scholar]
  34. Rehan M. Mostafa M. Virtual screening of 1,4-naphthoquinone derivatives for inhibition of a key cancer signaling protein, AKT1 kinase. Anticancer Res. 2019 39 7 3823 3833 10.21873/anticanres.13532 31262910
    [Google Scholar]
  35. O’Boyle N.M. Banck M. James C.A. Morley C. Vandermeersch T. Hutchison G.R. Open Babel: An open chemical toolbox. J. Cheminform. 2011 3 1 33 10.1186/1758‑2946‑3‑33 21982300
    [Google Scholar]
  36. Trott O. Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010 31 2 455 461 10.1002/jcc.21334 19499576
    [Google Scholar]
  37. Laskowski R.A. Swindells M.B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 2011 51 10 2778 2786 10.1021/ci200227u 21919503
    [Google Scholar]
  38. Wang R. Lai L. Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J. Comput. Aided Mol. Des. 2002 16 1 11 26 10.1023/A:1016357811882 12197663
    [Google Scholar]
  39. Pires D.E.V. Blundell T.L. Ascher D.B. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 2015 58 9 4066 4072 10.1021/acs.jmedchem.5b00104 25860834
    [Google Scholar]
  40. Abraham M.J. Murtola T. Schulz R. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015 1-2 19 25 10.1016/j.softx.2015.06.001
    [Google Scholar]
  41. Valdés-Tresanco M.S. Valdés-Tresanco M.E. Valiente P.A. Moreno E. gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. J. Chem. Theory Comput. 2021 17 10 6281 6291 10.1021/acs.jctc.1c00645 34586825
    [Google Scholar]
  42. David C.C. Jacobs D.J. Principal component analysis: A method for determining the essential dynamics of proteins. Methods Mol. Biol. 2014 1084 193 226 10.1007/978‑1‑62703‑658‑0_11 24061923
    [Google Scholar]
  43. Warren G.L. Andrews C.W. Capelli A.M. A critical assessment of docking programs and scoring functions. J. Med. Chem. 2006 49 20 5912 5931 10.1021/jm050362n 17004707
    [Google Scholar]
  44. Özen A. Prachanronarong K. Matthew A.N. Soumana D.I. Schiffer C.A. Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors. Crit. Rev. Biochem. Mol. Biol. 2019 54 1 11 26 10.1080/10409238.2019.1568962 30821513
    [Google Scholar]
  45. Bakulin I. Pasechnikov V. Varlamicheva A. Sannikova I. NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. World J. Hepatol. 2014 6 5 326 339 10.4254/wjh.v6.i5.326 24868326
    [Google Scholar]
  46. de Leuw P. Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect. Dis. 2017 5 Doc08 10.3205/id000034 30671330
    [Google Scholar]
  47. McCauley J.A. Rudd M.T. Hepatitis C virus NS3/4a protease inhibitors. Curr. Opin. Pharmacol. 2016 30 84 92 10.1016/j.coph.2016.07.015 27544488
    [Google Scholar]
  48. Venkatraman S. Njoroge F.G. Wu W. Novel inhibitors of hepatitis C NS3–NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid. Bioorg. Med. Chem. Lett. 2006 16 6 1628 1632 10.1016/j.bmcl.2005.12.046 16413182
    [Google Scholar]
  49. Copeland R.A. Evaluation of enzyme inhibitors in drug discovery: A guide for medicinal chemists and pharmacologists. Hoboken, NJ Wiley-Interscience 2005
    [Google Scholar]
  50. Shin J.S. Kim K.S. Kim M.B. Jeong J.H. Kim B.K. Synthesis and hypoglycemic effect of chrysin derivatives. Bioorg. Med. Chem. Lett. 1999 9 6 869 874 10.1016/S0960‑894X(99)00092‑X 10206552
    [Google Scholar]
  51. Hyup Joo Y. Kwan Kim J. Kang S.H. 2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 2003 13 3 413 417 10.1016/S0960‑894X(02)00952‑6 12565941
    [Google Scholar]
  52. Yang H. Xuefeng Y. Shandong W. Jianhua X. COX-2 in liver fibrosis. Clin. Chim. Acta 2020 506 196 203 10.1016/j.cca.2020.03.024 32184095
    [Google Scholar]
  53. Cheng A.S.L. Chan H.L.Y. Leung W.K. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod. Pathol. 2004 17 10 1169 1179 10.1038/modpathol.3800196 15218507
    [Google Scholar]
  54. Martín-Sanz P. Mayoral R. Casado M. Boscá L. COX-2 in liver, from regeneration to hepatocarcinogenesis: What we have learned from animal models? World J. Gastroenterol. 2010 16 12 1430 1435 10.3748/wjg.v16.i12.1430 20333781
    [Google Scholar]
  55. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat. Rev. 2006 32 1 28 44 10.1016/j.ctrv.2005.10.004 16337744
    [Google Scholar]
  56. Jeong S.W. Jang J.Y. Lee S.H. Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.) 2010 25 4 364 371 10.3904/kjim.2010.25.4.364 21179273
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128386884250904063752
Loading
Computational Exploration of Flavonoids as HCV NS3/4A Protease Inhibitors: Advancing Antiviral Therapies to Mitigate Liver Cancer Risk
Bentham Science Publishers ; https://doi.org/10.2174/0113816128386884250904063752
/content/journals/cpd/10.2174/0113816128386884250904063752
/content/journals/cpd/10.2174/0113816128386884250904063752
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: virtual screening ; flavonoids ; NS3 ; HCV ; molecular docking ; hepatocellular carcinoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test